These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide. Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201 [TBL] [Abstract][Full Text] [Related]
3. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice. Zhang RS; He Z; Jin WD; Wang R Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice. Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996 [TBL] [Abstract][Full Text] [Related]
5. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice. Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932 [TBL] [Abstract][Full Text] [Related]
6. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides. Wei F; Zhao L; Jing Y Neuropeptides; 2020 Feb; 79():101998. PubMed ID: 31831183 [TBL] [Abstract][Full Text] [Related]
7. An α-hemoglobin-derived peptide (m)VD-hemopressin (α) promotes NREM sleep via the CB Xie JF; Wang LX; Ren WT; Wang C; Gao JX; Chen HL; Zhao XQ; Ren YL; Xie YP; Shao YF; Hou YP Front Pharmacol; 2023; 14():1213215. PubMed ID: 37456761 [TBL] [Abstract][Full Text] [Related]
8. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. Bauer M; Chicca A; Tamborrini M; Eisen D; Lerner R; Lutz B; Poetz O; Pluschke G; Gertsch J J Biol Chem; 2012 Oct; 287(44):36944-67. PubMed ID: 22952224 [TBL] [Abstract][Full Text] [Related]
9. Hemopressin as a breakthrough for the cannabinoid field. Heimann AS; Dale CS; Guimarães FS; Reis RAM; Navon A; Shmuelov MA; Rioli V; Gomes I; Devi LL; Ferro ES Neuropharmacology; 2021 Feb; 183():108406. PubMed ID: 33212113 [TBL] [Abstract][Full Text] [Related]
10. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats. Li XH; Li N; Wang ZL; Pan JX; Han ZL; Chang XM; Tang HH; Wang P; Wang R; Fang Q Peptides; 2014 Jun; 56():45-51. PubMed ID: 24681436 [TBL] [Abstract][Full Text] [Related]
11. CB Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880 [TBL] [Abstract][Full Text] [Related]
13. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Heimann AS; Gomes I; Dale CS; Pagano RL; Gupta A; de Souza LL; Luchessi AD; Castro LM; Giorgi R; Rioli V; Ferro ES; Devi LA Proc Natl Acad Sci U S A; 2007 Dec; 104(51):20588-93. PubMed ID: 18077343 [TBL] [Abstract][Full Text] [Related]
14. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481 [TBL] [Abstract][Full Text] [Related]
15. Investigation of receptor binding and functional characteristics of hemopressin(1-7). Dvorácskó S; Tömböly C; Berkecz R; Keresztes A Neuropeptides; 2016 Aug; 58():15-22. PubMed ID: 26895730 [TBL] [Abstract][Full Text] [Related]
16. (m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice. Zhang R; Lao K; Lu B; Guo H; Cheng J; Chen P; Gou X Peptides; 2021 Feb; 136():170442. PubMed ID: 33171279 [TBL] [Abstract][Full Text] [Related]
17. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R Neurosci Lett; 2014 Aug; 578():187-91. PubMed ID: 25010019 [TBL] [Abstract][Full Text] [Related]
18. Characterization of pepcan-23 as pro-peptide of RVD-hemopressin (pepcan-12) and stability of hemopressins in mice. Glasmacher S; Gertsch J Adv Biol Regul; 2021 May; 80():100808. PubMed ID: 33799079 [TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice. Wang P; Zheng T; Zhang M; Xu B; Zhang R; Zhang T; Zhao W; Shi X; Zhang Q; Fang Q Brain Res Bull; 2018 May; 139():48-55. PubMed ID: 29425797 [TBL] [Abstract][Full Text] [Related]
20. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. Pan JX; Wang ZL; Li N; Zhang N; Wang P; Tang HH; Zhang T; Yu HP; Zhang R; Zheng T; Fang Q; Wang R Eur J Pharmacol; 2015 Nov; 767():119-25. PubMed ID: 26472125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]